Αρχική World News Prognostic Significance of Lynch-like versus Sporadic MSI-H Endometrial Cancer Treated With Pembrolizumab

Prognostic Significance of Lynch-like versus Sporadic MSI-H Endometrial Cancer Treated With Pembrolizumab

In a single-arm, open-label phase II study, the investigators led by Prof. Alessandro Santin of the Smilow Comprehensive Cancer Center, Yale University School of Medicine in New Haven, US evaluated pembrolizumab in patients with recurrent mismatch repair deficient (dMMR) and/or microsatellite instability-high (MSI-H) endometrial cancer. They wrote in the Annals of Oncology that their findings demonstrate the prognostic significance of Lynch-like versus sporadic MSI-H endometrial cancer on overall response rate (ORR), progression-free survival (PFS), and overall survival (OS).

Approximately one-third of endometrial cancers exhibit an MSI-H phenotype. However, these tumours originate from different pathways including germline mutations in MMR genes (Lynch syndrome), somatic MMR mutations (Lynch-like), or homozygous methylation of the MLH1 promoter (sporadic).

The study team explained that it is unclear whether mechanisms underlying MSI alter responses to immune checkpoint inhibitors (ICIs). The resistance to ICIs is not completely understood.

In total, 25 patients who received at least 1 prior chemotherapy line were accrued from September 2016 to March 2020 in the study (NCT02899793). They received pembrolizumab 200 mg intravenously every 3 weeks for up to 24 months. Primary endpoints were ORR per RECIST v1.1 and toxicity. Secondary endpoints included PFS and OS.

In total, 6 (25%) patients harboured Lynch-like tumours whereas 18 (75%) had sporadic endometrial cancer. There were no patients with germline Lynch. Tumour mutation burden was higher in Lynch-like versus sporadic tumours (p = 0.0076).

Upon median follow-up of 25.8 months, the ORR was 58% (95% confidence interval 36.6-77.9). The ORR was 100% in Lynch-like, but only 44% in sporadic tumours (p = 0.024). The 3-year PFS rate was 100% versus 30% (p = 0.017) and OS 100% versus 43% (p = 0.043).

Grade 3/4 treatment-related adverse events (6.8%) occurred in 12 patients.

Primary resistance was found in 4 patients (16.6%), including a mixed response in which all measurable lesions except one lung nodule decreased. Following resection, this patient continued pembrolizumab off-protocol and is progression-free at 41 months from study discontinuation.

Secondary resistance occurred in 7 cases, including 1 case of progression limited to a single abdominal lesion. Following resection, the patient continued pembrolizumab off-protocol and remains without disease at 42 months.

Lynch-like MSI-H endometrial cancer demonstrated significantly higher average infiltration of CD68+ macrophages in tumour/stroma (p = 0.022). No significant differences were noted in CD3+ T cells or CD20+ B cells. In total, 17 (70.8%) MSI-H patients had a combined positive score ≥1%, 5 of 6 (83.3%) of Lynch-like, and 12 of 18 (66.7%) of the methylated patients (Fisher’s exact p = 0.63).

The authors wrote that their study demonstrates the prognostic significance of Lynch-like versus sporadic MSI-H endometrial cancer. Clinical studies evaluating separate subtypes of MSI-H endometrial cancer treated with ICIs are warranted.

The study was supported by Merck USA, and in part by grants from the US National Institutes of Health (NIH), the Tina Brozman Foundation, the Guido Berlucchi Foundation, and Gilead Sciences Inc, the National Cancer Institute and Stand-Up-To-Cancer convergence grant.


Bellone S, Roque DM, Siegel ER, et al. A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793). Annals of Oncology 2021;32(8):1045-1046. DOI: https://doi.org/10.1016/j.annonc.2021.04.01



Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...


Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...


ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

Puppy That Was Born Dead Becomes Therapy Dog for Cancer Patient

This story has been shared as part of the Fur Fam Story Contest. You can submit your own tale through December 5th. Voting will...

ESMO Immuno-Oncology Congress 2021, Geneva, Switzerland, 8-11 December

LUGANO, Switzerland – The ESMO Immuno-Oncology Congress 2021, the European platform dedicated to the development and use of immunotherapies for cancer treatment, will be held...

Targeted drug recommended to treat some advanced lung cancer patients

Selpercatinib will expand treatment options available for people with RET fusion positive non small cell lung cancer. Non small cell lung cancer cells. The National Institute...

Withdrawal of Application to Change the EU Marketing Authorisation for Cervarix

The European Medicines Agency (EMA) announced on 12 November 2021 that GlaxoSmithKline Biologicals SA withdrew its application to use Cervarix (human papillomavirus vaccine ...

Robin Williams Required Film Companies He Worked With To Hire Homeless People

It’s been years since his passing, but the world still feels the loss of Robin Williams. Not only was he an extremely talented and funny...

Though the Pandemic Has Slowed, Many Are Still Struggling to Put Food on the Table

The COVID-19 pandemic wreaked havoc on the economy, leaving many people who had been comfortable suddenly struggling financially. Feeding America estimates that at least...